GSKGlaxoSmithKlineRunning, no new patients
Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
Multiple Myeloma
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 3
- Patients
- 494 (final count)
- Started
- May 7, 2020
- Main results expected
- Oct 2, 2023
- Fully finished
- Jun 30, 2028
- Results posted
- Oct 24, 2024
What counts as success
The trial's main goal(s), called the “primary outcome.”
Progression-free Survival (PFS)
Measured over: Up to approximately 41 months
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT04246047 · record last updated 2026-04-23 · checked 2026-11-09 15:47 UTC